Cat. No.: HY-N0176

Dihydroartemisinin

(Synonyms: Dihydroqinghaosu; β-Dihydroartemisinin; Artenimol)

45 Cited Publications

Avis client

Based on 45 publication(s) in Google Scholar

Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 98.0%
CAS No.: 71939-50-9
Formule: C₁₅H₂₄O₅
Masse moléculaire:284.35

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Dihydroartemisinin Chemical Structure

CAS No.: 71939-50-9

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (45)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

Schistosome

Voir tous les produits spécifiques à Isoform Parasite :

Voir tous les produits spécifiques à Isoform NF-κB :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	0.63 μM Compound: DHA	Anticancer activity against human 786-0 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human 786-0 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
A 172	IC₅₀	66 μM Compound: 37	Anticancer activity against human A-172 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human A-172 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
A2780	IC₅₀	1 μM Compound: 26; DHA	Growth inhibition of human A2780 cells incubated for 48 hrs by MTT assay Growth inhibition of human A2780 cells incubated for 48 hrs by MTT assay	[PMID: 32352776]
A-375	IC₅₀	>50 μM Compound: DHA	Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
A-375	IC₅₀	38.5 μM Compound: Dihydroartemisinin	Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
A-431	IC₅₀	42.44 μM Compound: Dihydroartemisinin	Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
A-431	IC₅₀	15.74 μM Compound: Dihydroartemisinin	Antiproliferative activity against human A-431 cells Antiproliferative activity against human A-431 cells	[PMID: 31945642]
A549	IC₅₀	0.63 μM Compound: 1b	Anticancer activity against human A549 cells by sulforhodamine B assay Anticancer activity against human A549 cells by sulforhodamine B assay	[PMID: 19819696]
A549	IC₅₀	30.1 μM Compound: DHA	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 26276433]
A549	IC₅₀	80.42 μM Compound: 1; DHA	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 26595184]
A549	IC₅₀	29.9 μM Compound: DHA	Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
A549	IC₅₀	46.8 μM Compound: Dihydroartemisinin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
A549	IC₅₀	45.33 μM Compound: 2; DHA	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 30837097]
A549	IC₅₀	42.44 μM Compound: Dihydroartemisinin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
A549	IC₅₀	5.29 μM Compound: Dihydroartemisinin	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 31945642]
A549	IC₅₀	27.8 μM Compound: 1; DHA	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 33691167]
A549	EC₅₀	>25 μM Compound: 7	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by WST-1 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by WST-1 assay	[PMID: 33901900]
A549	IC₅₀	>40 μM Compound: DHA; 2	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
A549	IC₅₀	0.23 μM Compound: DHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay	[PMID: 36538859]
A549	IC₅₀	76.21 μM Compound: DHA	Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by MTT assay	10.1007/s00044-012-0319-0
ADR5000 cell line	IC₅₀	0.27 μM Compound: 2, DHA	Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay	[PMID: 26260339]
ADR5000 cell line	EC₅₀	0.265 μM Compound: 2; DHA	Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	[PMID: 29887512]
ADR5000 cell line	IC₅₀	1.84 μM Compound: 2; DHA	Cytotoxicity against human CEM/ADR5000 cells by XTT assay Cytotoxicity against human CEM/ADR5000 cells by XTT assay	[PMID: 30837097]
BV-2	IC₅₀	120.3 μM Compound: DHA	Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability incubated for 24 hrs by crystal violet dye based assay Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability incubated for 24 hrs by crystal violet dye based assay	[PMID: 33852975]
BV-2	IC₅₀	7.4 μM Compound: DHA	Antiinflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced nitric oxide production incubated for 24 hrs by 2, 3-diaminonaphthalene based assay Antiinflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced nitric oxide production incubated for 24 hrs by 2, 3-diaminonaphthalene based assay	[PMID: 33852975]
C-33-A	EC₅₀	1.71 μM Compound: DHA; 6	Antiproliferative activity against human C33A cells after 72 hrs by MTT assay Antiproliferative activity against human C33A cells after 72 hrs by MTT assay	[PMID: 30429957]
Caco-2	IC₅₀	26.87 μM Compound: 2a	Cytotoxicity against human Caco2 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 23103096]
CCRF-CEM	IC₅₀	0.09 μM Compound: 2, DHA	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay	[PMID: 26260339]
CCRF-CEM	EC₅₀	0.085 μM Compound: 2; DHA	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	[PMID: 29887512]
CCRF-CEM	IC₅₀	0.87 μM Compound: 2; DHA	Cytotoxicity against human CCRF-CEM cells by XTT assay Cytotoxicity against human CCRF-CEM cells by XTT assay	[PMID: 30837097]
CCRF-CEM	IC₅₀	5.127 μM Compound: DHA; 2	Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
CD4+ve Th	IC₅₀	4.03 μM Compound: 2; DHA	Inhibition of human CD4+ve Th cell proliferation Inhibition of human CD4+ve Th cell proliferation	[PMID: 32631539]
CHO	IC₅₀	147.7 μM Compound: DHA	Cytotoxicity against CHO cells after 48 hrs by MTT assay Cytotoxicity against CHO cells after 48 hrs by MTT assay	[PMID: 24602791]
CHO	IC₅₀	>100 μM Compound: DHA	Cytotoxicity against CHO cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27448920]
CHO	IC₅₀	>100 μM Compound: DHA	Cytotoxicity against CHO cells assessed as reduction in cell viability by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability by MTT assay	[PMID: 32987134]
CNE	IC₅₀	18.4 μM Compound: 37	Anticancer activity against human CNE cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human CNE cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
COLO 205	IC₅₀	42.44 μM Compound: Dihydroartemisinin	Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
COLO 205	IC₅₀	15.74 μM Compound: Dihydroartemisinin	Antiproliferative activity against human COLO 205 cells Antiproliferative activity against human COLO 205 cells	[PMID: 31945642]
Ehrlich	IC₅₀	83.4 μM Compound: 2	Cytotoxicity against mouse EAC after 3 days by MTT assay Cytotoxicity against mouse EAC after 3 days by MTT assay	[PMID: 8350087]
Erythrocyte	IC₅₀	0.031 μM Compound: Dihydroartemisinin	Antimalarial activity against chloroquine sensitive Plasmodium falciparum 3D7 infected in human RBC assessed as parasite growth inhibition incubated for 72 hrs by SYBR Green dye based fluorescence assay Antimalarial activity against chloroquine sensitive Plasmodium falciparum 3D7 infected in human RBC assessed as parasite growth inhibition incubated for 72 hrs by SYBR Green dye based fluorescence assay	[PMID: 36561069]
HCT-116	IC₅₀	32.8 μM Compound: DHA	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
HCT-116	IC₅₀	>40 μM Compound: DHA; 2	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
HCT-116	IC₅₀	13.6 μM Compound: DHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by Cell-titer Glo luminescent assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by Cell-titer Glo luminescent assay	[PMID: 38287228]
HCT-116	IC₅₀	95.41 μM Compound: DHA	Cytotoxicity against Homo sapiens (human) HCT116 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HCT116 cells after 48 hr by MTT assay	10.1007/s00044-012-0319-0
HCT-15	IC₅₀	0.46 μM Compound: 1b	Anticancer activity against human HCT15 cells by sulforhodamine B assay Anticancer activity against human HCT15 cells by sulforhodamine B assay	[PMID: 19819696]
HEK293	IC₅₀	9.9 μM Compound: Dihydroartemisinin	Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay	[PMID: 29236492]
HEK293	IC₅₀	15.74 μM Compound: Dihydroartemisinin	Antiproliferative activity against human HEK293 cells Antiproliferative activity against human HEK293 cells	[PMID: 31945642]
HEK293	IC₅₀	>4 μM Compound: Dihydroartemisinin	Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue dye based fluorescence assay Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue dye based fluorescence assay	[PMID: 36799121]
HeLa	IC₅₀	>100 μM Compound: DHA	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 22858300]
HeLa	EC₅₀	10.46 μM Compound: DHA; 6	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30429957]
HeLa	IC₅₀	2.66 μM Compound: DHA	Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
HeLa	IC₅₀	8.85 μM Compound: DHA	Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay	10.1007/s00044-012-0319-0
HEp-2	IC₅₀	18.1 μM Compound: 37	Anticancer activity against human HEp-2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human HEp-2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
HepG2	IC₅₀	70 μM Compound: DHA	Cytotoxicity against human HepG2 cells after 72 hrs by formazan test Cytotoxicity against human HepG2 cells after 72 hrs by formazan test	[PMID: 23685181]
HepG2	IC₅₀	<1 μM Compound: Dihydroartemisinin	Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin	[PMID: 23927658]
HepG2	IC₅₀	29 μM Compound: 2; DHA	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27371926]
HepG2	IC₅₀	31.71 μM Compound: 2; DHA	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 30837097]
HepG2	IC₅₀	63.7 μM Compound: Dihydroartemisinin	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 31546197]
HepG2	IC₅₀	63.7 μM Compound: Dihydroartemisinin	Antiproliferative activity against human HepG2 cells Antiproliferative activity against human HepG2 cells	[PMID: 31945642]
HepG2	IC₅₀	73.6 μM Compound: 1; DHA	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 33691167]
HepG2	IC₅₀	30.13 μM Compound: DHA	Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay	10.1007/s00044-012-0319-0
HL-60	IC₅₀	1.56 μM Compound: 2, DHA	Cytotoxicity against human HL60 cells assessed as LDH release after 72 hrs Cytotoxicity against human HL60 cells assessed as LDH release after 72 hrs	[PMID: 17227762]
HL-60	IC₅₀	2.41 μM Compound: 2, DHA	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 17227762]
HL-60	IC₅₀	2.41 μM Compound: 4	Anticancer activity against human HL60 cells by MTT assay Anticancer activity against human HL60 cells by MTT assay	[PMID: 19136263]
HL-60	IC₅₀	2.41 μM Compound: DHA	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19249201]
HL-60	IC₅₀	2.9 μM Compound: 2, DHA	Cytotoxicity against human HL60 cells after 72 hrs by trypan blue exclusion assay Cytotoxicity against human HL60 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19501507]
HL-60	IC₅₀	2.4 μM Compound: 5	Antitumor activity against human HL60 cells after 72 hrs by MTT assay Antitumor activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20227283]
HL-60	IC₅₀	>20 μM Compound: DHA	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay in presence of DFOM Cytotoxicity against human HL60 cells after 48 hrs by MTT assay in presence of DFOM	[PMID: 22575162]
HL-60	IC₅₀	0.18 μM Compound: DHA	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay in absence of DFOM Cytotoxicity against human HL60 cells after 48 hrs by MTT assay in absence of DFOM	[PMID: 22575162]
HL-60	IC₅₀	0.26 μM Compound: DHA	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 22575162]
HL-60	IC₅₀	0.4 μM Compound: DHA	Cytotoxicity against human HL60 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24148834]
HL-60	IC₅₀	18.7 μM Compound: DHA	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 26276433]
HL-60	IC₅₀	2 μM Compound: 2; DHA	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27371926]
HL-60	GI₅₀	0.191 μM Compound: DHA	Antiproliferative activity against human HL60 cells after 96 hrs by MTT assay Antiproliferative activity against human HL60 cells after 96 hrs by MTT assay	[PMID: 29102180]
HL-60	IC₅₀	39.9 μM Compound: Dihydroartemisinin	Antiproliferative activity against human HL60 cells by MTT assay Antiproliferative activity against human HL60 cells by MTT assay	[PMID: 31546197]
HL-60	IC₅₀	0.299 μM Compound: Dihydroartemisinin	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability measured after 72 hrs Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability measured after 72 hrs	[PMID: 31945642]
HL-60	IC₅₀	39.9 μM Compound: Dihydroartemisinin	Anticancer activity against human HL-60 cells Anticancer activity against human HL-60 cells	[PMID: 31945642]
HL-60	IC₅₀	61.176 μM Compound: DHA; 2	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
HL-60	IC₅₀	6.82 μM Compound: 37	Anticancer activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
HL-60	IC₅₀	<1 μM Compound: DHA	Cytotoxicity against Homo sapiens (human) HL60 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HL60 cells after 48 hr by MTT assay	10.1007/s00044-012-0319-0
HT-1080	IC₅₀	49.14 μM Compound: DHA	Cytotoxicity against Homo sapiens (human) HT1080 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HT1080 cells after 48 hr by MTT assay	10.1007/s00044-012-0319-0
HT-29	IC₅₀	>100 μM Compound: DHA	Cytotoxicity against human HT-29 cells after 96 hrs under normoxic condition by MTT assay Cytotoxicity against human HT-29 cells after 96 hrs under normoxic condition by MTT assay	[PMID: 29649740]
HT-29	IC₅₀	18.52 μM Compound: DHA	Cytotoxicity against human HT-29 cells after 96 hrs under hypoxic condition by MTT assay Cytotoxicity against human HT-29 cells after 96 hrs under hypoxic condition by MTT assay	[PMID: 29649740]
HT-29	IC₅₀	5.29 μM Compound: Dihydroartemisinin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability	[PMID: 31945642]
Huh-7	CC₅₀	44.94 μM Compound: GNF-Pf-5634	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]
Huh-7	CC₅₀	>100 μg/mL Compound: DHA	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36306538]
HUVEC	IC₅₀	8.91 μM Compound: 2	Inhibitory activity against human umbilical vein endothelial cells (HUVEC) was assayed using MTT colorimetric proliferation assay Inhibitory activity against human umbilical vein endothelial cells (HUVEC) was assayed using MTT colorimetric proliferation assay	[PMID: 14552753]
HUVEC	IC₅₀	1.4 μM Compound: 1A; DHA	Cytotoxicity against HUVEC assessed as reduction in cell number after 48 hrs by MTT assay Cytotoxicity against HUVEC assessed as reduction in cell number after 48 hrs by MTT assay	[PMID: 28549888]
HUVEC	IC₅₀	180.1 μM Compound: 1; DHA	Cytotoxicity against HUVEC assessed as reduction in cell viability by MTT assay Cytotoxicity against HUVEC assessed as reduction in cell viability by MTT assay	[PMID: 33691167]
J774	EC₅₀	1.53 μM Compound: DHA	Cytotoxicity against mouse J774 cells Cytotoxicity against mouse J774 cells	[PMID: 27291102]
J774	EC₅₀	1.5 μM Compound: DHA	Cytotoxicity against mouse J774 cells after 72 hrs by CellTiter-96 aqueous one solution cell proliferation assay Cytotoxicity against mouse J774 cells after 72 hrs by CellTiter-96 aqueous one solution cell proliferation assay	[PMID: 29215279]
J82	IC₅₀	146.2 μM Compound: 1; DHA	Cytotoxicity in human J82 cells assessed as reduction in cell viability by MTT assay Cytotoxicity in human J82 cells assessed as reduction in cell viability by MTT assay	[PMID: 33691167]
Jurkat	IC₅₀	0.65 μM Compound: 2, DHA	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 17227762]
Jurkat	IC₅₀	5.21 μM Compound: DHA	Anticancer activity against human Jurkat cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human Jurkat cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
K562	GI₅₀	>10 μM Compound: DHA	Antiproliferative activity against human K562 cells after 96 hrs by MTT assay Antiproliferative activity against human K562 cells after 96 hrs by MTT assay	[PMID: 29102180]
K562	IC₅₀	42.44 μM Compound: Dihydroartemisinin	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
K562	IC₅₀	15.74 μM Compound: Dihydroartemisinin	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 31945642]
K562	IC₅₀	21.828 μM Compound: DHA; 2	Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
K562	IC₅₀	9.81 μM Compound: DHA	Cytotoxicity against Homo sapiens (human) K562 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) K562 cells after 48 hr by MTT assay	10.1007/s00044-012-0319-0
KB	IC₅₀	95.3 μM Compound: Dihydroartemisinin	Antiproliferative activity against human KB cells by MTT assay Antiproliferative activity against human KB cells by MTT assay	[PMID: 31546197]
KB	IC₅₀	95.3 μM Compound: Dihydroartemisinin	Antiproliferative activity against human KB cells Antiproliferative activity against human KB cells	[PMID: 31945642]
L02	IC₅₀	34.9 μM Compound: DHA	Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay	[PMID: 26276433]
L02	IC₅₀	145.9 μM Compound: 1; DHA	Cytotoxicity against human L02 cells after 72 hrs by MTT assay Cytotoxicity against human L02 cells after 72 hrs by MTT assay	[PMID: 26595184]
L02	IC₅₀	>50 μM Compound: DHA	Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
L02	IC₅₀	34 μM Compound: Dihydroartemisinin	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
L02	IC₅₀	40.21 μM Compound: 2; DHA	Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay	[PMID: 30837097]
L02	IC₅₀	0.36 μM Compound: 1; DHA	Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay	[PMID: 30852384]
L02	IC₅₀	24.332 μM Compound: DHA; 2	Antiproliferative activity against human L02 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
L6	IC₅₀	0.73 μM Compound: 5, diastereomeric mixture	Cytotoxicity against rat L6 cells after 70 hrs by Alamar Blue assay Cytotoxicity against rat L6 cells after 70 hrs by Alamar Blue assay	[PMID: 24900723]
Lewis lung carcinoma cell line	IC₅₀	53.14 μM Compound: DHA	Antiproliferative activity against mouse Lewis lung carcinoma cell line assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against mouse Lewis lung carcinoma cell line assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36538859]
LNCaP	GI₅₀	>10 μM Compound: DHA	Antiproliferative activity against human LNCAP cells after 96 hrs by MTT assay Antiproliferative activity against human LNCAP cells after 96 hrs by MTT assay	[PMID: 29102180]
LS174T	IC₅₀	120 μM Compound: DHA	Cytotoxicity against human LS 174T cells after 72 hrs by formazan test Cytotoxicity against human LS 174T cells after 72 hrs by formazan test	[PMID: 23685181]
LS180	IC₅₀	32 μM Compound: 2; DHA	Cytotoxicity against human LS180 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human LS180 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27371926]
Lu1	IC₅₀	39.9 μM Compound: Dihydroartemisinin	Antiproliferative activity against human Lu1 cells by MTT assay Antiproliferative activity against human Lu1 cells by MTT assay	[PMID: 31546197]
MCF7	IC₅₀	45.23 μM Compound: DHA	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19249201]
MCF7	GI₅₀	33.22 μM Compound: DHA	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 26741854]
MCF7	GI₅₀	33.22 μM Compound: DHA	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 29102180]
MCF7	IC₅₀	>50 μM Compound: Dihydroartemisinin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
MCF7	EC₅₀	8.24 μM Compound: DHA; 6	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30429957]
MCF7	IC₅₀	34.29 μM Compound: 2; DHA	Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay	[PMID: 30837097]
MCF7	IC₅₀	39.9 μM Compound: Dihydroartemisinin	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 31546197]
MCF7	IC₅₀	39.9 μM Compound: Dihydroartemisinin	Anticancer activity against human MCF7 cells Anticancer activity against human MCF7 cells	[PMID: 31945642]
MCF7	IC₅₀	39.9 μM Compound: Dihydroartemisinin	Anticancer activity against human MCF7 cells assessed as inhibition of cell growth Anticancer activity against human MCF7 cells assessed as inhibition of cell growth	[PMID: 31945642]
MCF7	IC₅₀	6.88 μM Compound: DHA	Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
MCF7	IC₅₀	50.18 μM Compound: DHA	Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay	10.1007/s00044-012-0319-0
MDA-MB-231	IC₅₀	99.76 μM Compound: DHA	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 19249201]
MDA-MB-231	GI₅₀	12.58 μM Compound: DHA	Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by MTT assay	[PMID: 29102180]
MDA-MB-231	IC₅₀	47.11 μM Compound: DHA	Cytotoxicity against human MDA-MB-231 cells after 96 hrs under normoxic condition by MTT assay Cytotoxicity against human MDA-MB-231 cells after 96 hrs under normoxic condition by MTT assay	[PMID: 29649740]
MDA-MB-231	IC₅₀	5.64 μM Compound: DHA	Cytotoxicity against human MDA-MB-231 cells after 96 hrs under hypoxic condition by MTT assay Cytotoxicity against human MDA-MB-231 cells after 96 hrs under hypoxic condition by MTT assay	[PMID: 29649740]
MDA-MB-231	IC₅₀	45.7 μM Compound: Dihydroartemisinin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
MDA-MB-231	EC₅₀	10.69 μM Compound: DHA; 6	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 30429957]
MDA-MB-231	IC₅₀	58.69 μM Compound: 2; DHA	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	[PMID: 30837097]
MDA-MB-231	IC₅₀	42.44 μM Compound: Dihydroartemisinin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
MDA-MB-361	EC₅₀	1.71 μM Compound: DHA; 6	Antiproliferative activity against human MDA-MB-361 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-361 cells after 72 hrs by MTT assay	[PMID: 30429957]
MDA-MB-435S	IC₅₀	21.92 μM Compound: 1; DHA	Antiproliferative activity against human MDA-MB-435S cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-435S cells after 72 hrs by MTT assay	[PMID: 26595184]
MIA PaCa-2	IC₅₀	58 μM Compound: 2; DHA	Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27371926]
NB-4	GI₅₀	0.151 μM Compound: DHA	Antiproliferative activity against human NB4 cells after 96 hrs by MTT assay Antiproliferative activity against human NB4 cells after 96 hrs by MTT assay	[PMID: 29102180]
NCI/ADR-RES	GI₅₀	3.32 μM Compound: DHA	Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay	[PMID: 26741854]
NCI/ADR-RES	GI₅₀	3.32 μM Compound: DHA	Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay	[PMID: 29102180]
NCI-H460	IC₅₀	5.29 μM Compound: Dihydroartemisinin	Antiproliferative activity against human NCI-H460 cells Antiproliferative activity against human NCI-H460 cells	[PMID: 31945642]
OVCAR-3	IC₅₀	1 μM Compound: 26; DHA	Growth inhibition of human OVCAR3 cells incubated for 48 hrs by MTT assay Growth inhibition of human OVCAR3 cells incubated for 48 hrs by MTT assay	[PMID: 32352776]
OVCAR-3	IC₅₀	87.2 μM Compound: 1; DHA	Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability by MTT assay	[PMID: 33691167]
P388	IC₅₀	39.9 μM Compound: Dihydroartemisinin	Antiproliferative activity against mouse P388 cells by MTT assay Antiproliferative activity against mouse P388 cells by MTT assay	[PMID: 31546197]
P388	IC₅₀	39.9 μM Compound: Dihydroartemisinin	Anticancer activity against mouse P388 cells Anticancer activity against mouse P388 cells	[PMID: 31945642]
P388/ADR	IC₅₀	20.67 μM Compound: Dihydroartemisinin	Antiproliferative activity against mouse P388/ADR cells assessed as reduction in cell viability measured after 72 hrs Antiproliferative activity against mouse P388/ADR cells assessed as reduction in cell viability measured after 72 hrs	[PMID: 31945642]
PBMC	IC₅₀	>250 μM Compound: 2, DHA	Cytotoxicity against human PBMC after 72 hrs by MTT assay Cytotoxicity against human PBMC after 72 hrs by MTT assay	[PMID: 17227762]
PC-12	IC₅₀	>50 μM Compound: DHA	Antiproliferative activity against rat PC12 cells after 72 hrs by CCK-8 assay Antiproliferative activity against rat PC12 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
PC-3	IC₅₀	>100 μM Compound: 1; DHA	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 26595184]
PC-3	IC₅₀	>100 μM Compound: 2; DHA	Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27371926]
PC-3	GI₅₀	>10 μM Compound: DHA	Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay	[PMID: 29102180]
PC-3	IC₅₀	42.44 μM Compound: Dihydroartemisinin	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
PC-3	IC₅₀	15.74 μM Compound: Dihydroartemisinin	Antiproliferative activity against human PC-3 cells Antiproliferative activity against human PC-3 cells	[PMID: 31945642]
PC-3	IC₅₀	2.49 μM Compound: DHA	Anticancer activity against human PC-3 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human PC-3 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
SGC-7901	IC₅₀	>100 μM Compound: 1; DHA	Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 26595184]
SH-SY5Y	IC₅₀	>50 μM Compound: DHA	Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
SH-SY5Y	IC₅₀	>50 μM Compound: Dihydroartemisinin	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
SH-SY5Y	IC₅₀	>40 μM Compound: DHA; 2	Antiproliferative activity against human SH-SY5Y cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human SH-SY5Y cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
SiHa	EC₅₀	29.8 μM Compound: DHA; 6	Antiproliferative activity against human SiHa cells after 72 hrs by MTT assay Antiproliferative activity against human SiHa cells after 72 hrs by MTT assay	[PMID: 30429957]
SK-HEP1	IC₅₀	30 μM Compound: DHA	Cytotoxicity against human SKHEP1 cells after 72 hrs by formazan test Cytotoxicity against human SKHEP1 cells after 72 hrs by formazan test	[PMID: 23685181]
SK-MEL-2	IC₅₀	0.75 μM Compound: 1b	Anticancer activity against human SK-MEL-2 cells by sulforhodamine B assay Anticancer activity against human SK-MEL-2 cells by sulforhodamine B assay	[PMID: 19819696]
SK-OV-3	IC₅₀	0.85 μM Compound: 1b	Anticancer activity against human SKOV3 cells by sulforhodamine B assay Anticancer activity against human SKOV3 cells by sulforhodamine B assay	[PMID: 19819696]
SMMC-7721	IC₅₀	13.8 μM Compound: DHA	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 26276433]
SMMC-7721	IC₅₀	>0.1 μM Compound: 1; DHA	Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay	[PMID: 30852384]
SMMC-7721	IC₅₀	0.4 μM Compound: Dihydroartemisinin	Antiproliferative activity against human SMMC-7721 cells Antiproliferative activity against human SMMC-7721 cells	[PMID: 31945642]
SMMC-7721	IC₅₀	61.4 μM Compound: 1; DHA	Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 33691167]
SW480	IC₅₀	>100 μM Compound: DHA	Cytotoxicity against human SW480 cells after 48 hrs by MTT assay Cytotoxicity against human SW480 cells after 48 hrs by MTT assay	[PMID: 26276433]
T47D	EC₅₀	4.6 μM Compound: DHA; 6	Antiproliferative activity against human T47D cells after 72 hrs by MTT assay Antiproliferative activity against human T47D cells after 72 hrs by MTT assay	[PMID: 30429957]
THP-1	IC₅₀	9.05 μM Compound: 37	Anticancer activity against human THP-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human THP-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
U-373MG ATCC	IC₅₀	1.17 μg/mL Compound: DHA	Cytotoxicity against human U373 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human U373 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31784199]
U-87MG ATCC	IC₅₀	>50 μM Compound: Dihydroartemisinin	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
U-87MG ATCC	IC₅₀	5.29 μM Compound: Dihydroartemisinin	Antiproliferative activity against human U-87 MG cells Antiproliferative activity against human U-87 MG cells	[PMID: 31945642]
U-87MG ATCC	IC₅₀	50 μM Compound: 37	Anticancer activity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
U-937	GI₅₀	0.91 μM Compound: DHA	Antiproliferative activity against human U937 cells after 96 hrs by MTT assay Antiproliferative activity against human U937 cells after 96 hrs by MTT assay	[PMID: 29102180]
U-937	IC₅₀	<1 μM Compound: DHA	Cytotoxicity against Homo sapiens (human) U937 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) U937 cells after 48 hr by MTT assay	10.1007/s00044-012-0319-0
XF498	IC₅₀	0.54 μM Compound: 1b	Anticancer activity against human XF498 cells by sulforhodamine B assay Anticancer activity against human XF498 cells by sulforhodamine B assay	[PMID: 19819696]

In Vitro

Dihydroartemisinin (10-40 μM; 24 h) induces functional autophagy, including mitophagy, in human multiple myeloma RPMI 8226 cells in vitro in a dose-dependent manner, with significant effects observed at 10, 20, and 40 μM over 24 h^[1].
Dihydroartemisinin (10-40 μM; 12 h) suppresses NF-κB activity in human multiple myeloma RPMI 8226 cells by inhibiting IκBα phosphorylation, preventing RelA/p65 nuclear translocation, and reducing DNA-binding activity, with this inhibition contributing to DHA-induced apoptosis^[1].
Dihydroartemisinin (10-40 μM; 15-24 h) induces autophagy in human multiple myeloma RPMI 8226 cells and human promyelocytic leukemia NB4 cells that relies on NF-κB inhibition-mediated reduction of FHC and MnSOD, leading to ROS accumulation that drives autophagic activation^[1].
Dihydroartemisinin (2.5-120 μmol/L; 24 h) reduces the viability of human esophageal cancer Eca109 and Ec9706 cells in vitro in a dose-dependent manner after 24 h of incubation^[2].
Dihydroartemisinin (80 μmol/L; 24 h) sensitizes human esophageal cancer Eca109 and Ec9706 cells to photodynamic therapy-induced apoptosis, increasing the apoptosis rate to 20.9% in Eca109 cells and 21.8% in Ec9706 cells, which is significantly greater than either single treatment^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Autophagy Assay^[1]

Cell Line:

human multiple myeloma RPMI 8226 cells
Concentration:

10 μM, 20 μM, 40 μM
Incubation Time:

24 h
Result:

Induced dose-dependent accumulation of AVOs (12.5% AVO-positive cells at 20 μM, 17% at 40 μM).
Increased LC3-II protein levels in a dose-dependent manner.
Decreased p62 protein levels in a dose-dependent manner.
Further increased LC3-II levels when cotreated with CQ compared to DHA alone.
Increased autophagic vacuoles and autophagosomes containing damaged mitochondria via transmission electron microscopy.
Increased colocalization of LC3 puncta with mitochondria via immunofluorescence.

Cell Viability Assay^[2]

Cell Line:

human esophageal cancer Eca109 and Ec9706 cells
Concentration:

2.5-120 μmol/L
Incubation Time:

24 h
Result:

Reduced the viability of Eca109 and Ec9706 cells in a dose-dependent manner relative to untreated cells.

Apoptosis Analysis^[2]

Cell Line:

human esophageal cancer Eca109 and Ec9706 cells (combined with photodynamic therapy)
Concentration:

80 μmol/L
Incubation Time:

24 h
Result:

Increased the apoptosis rate from 7.7% to 12.1% in Eca109 cells and from 5.5% to 12.7% in Ec9706 cells when used as single treatment.
Increased the apoptosis rate to 20.9% in Eca109 cells and 21.8% in Ec9706 cells when combined with PDT, a significantly greater increase than either single treatment (p<0.05).

In Vivo

Dihydroartemisinin (200-600 mg/kg; p.o.; once daily; for 3 consecutive days) reduces the total worm burden of schistosomula in Kunming mice infected with S. japonicum by 69.2%-90.6%^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Kunming strain (20-24 g, percutaneously infected with 39-41 Schistosoma japonicum cercariae)^[3]
Dosage:

200 mg/kg; 300 mg/kg; 400 mg/kg; 600 mg/kg
Administration:

p.o.; daily; 3 days
Result:

Reduced total-worm burden by 69.2% and female-worm burden by 62.2% when administered on days 6-8 post-infection at 200 mg/kg.
Reduced total-worm burden by 80.7% and female-worm burden by 75.6% when administered on days 6-8 post-infection at 300 mg/kg.
Reduced total-worm burden by 87.1% (statistically greater than 200 mg/kg) and female-worm burden by 87.1% when administered on days 6-8 post-infection at 400 mg/kg.
Reduced total-worm burden by 90.6% (statistically greater than 200 mg/kg) and female-worm burden by 90.2% when administered on days 6-8 post-infection at 600 mg/kg.
Reduced total-worm burden by 73.9% and female-worm burden by 83.8% when administered on days 34-36 post-infection at 200 mg/kg.
Reduced total-worm burden by 75.0% and female-worm burden by 92.9% when administered on days 34-36 post-infection at 300 mg/kg.
Reduced total-worm burden by 84.2% and female-worm burden by 94.1% (statistically greater than 200 mg/kg) when administered on days 34-36 post-infection at 400 mg/kg.
Reduced total-worm burden by 85.5% and female-worm burden by 95.3% (statistically greater than 200 mg/kg) when administered on days 34-36 post-infection at 600 mg/kg.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 71939-50-9
Appearance Solid
Masse moléculaire 284.35
Formule C₁₅H₂₄O₅
Color White to off-white
SMILES

O[C@@H]1[C@H](C)[C@]2([H])CC[C@@H](C)[C@]3([H])CC[C@@](O4)(C)OO[C@]32[C@]4([H])O1
Synonyms

Dihydroqinghaosu; β-Dihydroartemisinin; Artenimol
Structure Classification
- Terpenoids
- Sesquiterpenes
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (45)

All WBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

J Adv Res

Neonatal sevoflurane exposures inhibits DHHC5-mediated palmitoylation of TfR1 in oligodendrocytes, leading to hypomyelination and neurological impairments. [Abstract]

2025 Feb 8:S2090-1232(25)00107-9. PMID: 39929269
Research (Wash D C)

Dihydroartemisinin Regulated the MMP-Mediated Cellular Microenvironment to Alleviate Rheumatoid Arthritis. [Abstract]

2024 Sep 10:7:0459. PMID: 39257420
Cell Death Dis

Trifluridine/tipiracil induces ferroptosis by targeting p53 via the p53-SLC7A11 axis in colorectal cancer 3D organoids. [Abstract]

2025 Apr 5;16(1):255. PMID: 40188162
Pharmacol Res

Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer. [Abstract]

2021 Aug:170:105701. PMID: 34087353
Cell Commun Signal

Lamprey immune protein triggers the ferroptosis pathway during zebrafish embryonic development. [Abstract]

2022 Aug 17;20(1):124. PMID: 35978430
Phytomedicine

Dihydroartemisinin alleviates sepsis-associated encephalopathy by reducing microglial iron accumulation and mitochondrial dysfunction via HIF1A/HMOX1 pathway. [Abstract]

2025 Nov 25:148:157413. PMID: 41135271
BMC Med

Helicobacter pylori SlyD stabilizes TPT1 via hnRNPK and enhances OCT1-mediated CDX2 transcriptional activation to drive gastric intestinal metaplasia. [Abstract]

2025 Feb 6;23(1):71. PMID: 39915880
Arch Pharm Res

Dihydroartemisinin inhibits follicular helper T and B cells: implications for systemic lupus erythematosus treatment. [Abstract]

2024 Jul;47(7):632-644. PMID: 38977652
Free Radic Biol Med

Mifepristone protects acetaminophen induced liver injury through NRF2/GSH/GST mediated ferroptosis suppression. [Abstract]

2024 Sep:222:229-243. PMID: 38906233
Pharmaceutics

Building of CuO2@Cu-TA@DSF/DHA Nanoparticle Targets MAPK Pathway to Achieve Synergetic Chemotherapy and Chemodynamic for Pancreatic Cancer Cells. [Abstract]

2024 Dec 19;16(12):1614. PMID: 39771592
CNS Neurosci Ther

Dihydroartemisinin Alleviates Neuronal Damage and Seizures in Epileptic Mice by Inhibiting Ferroptosis via the SIRT1/FOXO1/SLC7A11/GPX4 Pathway. [Abstract]

2026 Feb;32(2):e70798. PMID: 41718043
Cell Mol Life Sci

The contrasting effects of two antimalarial drugs on insulin secretion. [Abstract]

2025 Nov 25;82(1):419. PMID: 41288707
Food Biosci

2025 Apr 21.
Food Biosci

2024 Jul 14.
Inflamm Res

Dihydroartemisinin alleviates AngII-induced vascular smooth muscle cell proliferation and inflammatory response by blocking the FTO/NR4A3 axis. [Abstract]

2022 Feb;71(2):243-253. PMID: 35059772
Drug Des Devel Ther

Dihydroartemisinin Inhibits TGF-β-Induced Fibrosis in Human Tenon Fibroblasts via Inducing Autophagy. [Abstract]

2021 Mar 3:15:973-981. PMID: 33688170
Int J Mol Sci

Dihydroartemisinin Induces Ferroptosis in Uveal Melanoma Cells Through the HO-1 and xCT/GPX4 Signaling Pathways. [Abstract]

2026 Mar 26;27(7):3027. PMID: 41977217
Int Immunopharmacol

Mechanism of dihydroartemisinin in the treatment of ischaemia/reperfusion-induced acute kidney injury via network pharmacology, molecular dynamics simulation and experiments. [Abstract]

2025 Jan 10:144:113705. PMID: 39626534
Int J Mol Sci

Oxymatrine Ameliorates Lupus Nephritis by Targeting the YY1-Mediated IL-6/STAT3 Axis. [Abstract]

2024 Nov 14;25(22):12260. PMID: 39596325
Immunology

Dihydroartemisinin Alleviates Chronic Allograft Rejection by Inhibiting Tfh and B Cells While Promoting Treg Cells in Murine Cardiac Transplantation. [Abstract]

2025 Dec 23. PMID: 41437677
Sci Rep

Dihydroartemisinin ameliorates renal tubulointerstitial fibrosis in diabetic nephropathy via restoring mitochondrial function via HIF-1α/HO-1 pathway. [Abstract]

2025 Sep 30;15(1):34106. PMID: 41028107
Comput Struct Biotechnol J

Severe fever with thrombocytopenia syndrome virus (SFTSV)-host interactome screen identifies viral nucleoprotein-associated host factors as potential antiviral targets. [Abstract]

2021 Oct 1:19:5568-5577. PMID: 34712400
Cell Signal

HDAC inhibitor enhances ferroptosis susceptibility of AML cells by stimulating iron metabolism. [Abstract]

2025 Mar:127:111583. PMID: 39756501
iScience

Identification of antimalarial drugs and bradykinin as ligands of the Plasmodium membrane protein PfSR10. [Abstract]

2025 Oct 21;28(11):113807. PMID: 41280702
Naunyn Schmiedebergs Arch Pharmacol

Enhancing sensitivity to oxaliplatin in tongue squamous cell carcinoma: mechanistic insights and therapeutic potential of DHA combination therapy. [Abstract]

2025 Apr;398(4):4393-4407. PMID: 39476243
INT J ADHES ADHES

2023 Feb 10.
Biomed Mater

Gold nanoparticles/Cu decorated metal-organic frameworks for synergistic photodynamic/ferroptosis cancer therapy. [Abstract]

2025 Mar 7;20(2). PMID: 39999568
J Biochem Mol Toxicol

Dihydroartemisinin Suppresses LOXL2-Mediated Glycerophospholipid Metabolic Reprogramming to Induce Cuproptosis in Colorectal Cancer Cells. [Abstract]

2025 Aug;39(8):e70420. PMID: 40746272
J Biochem Mol Toxicol

Dihydroartemisinin Targets the NFIC/FBN1 Cascade to Enhance Wound Healing in Chronic Skin Ulcer by Inhibiting Fibroblast Ferroptosis. [Abstract]

2025 May;39(5):e70297. PMID: 40358939
Neuroscience

Dihydroartemisinin protects mice from CUMS-induced depression-like behaviors and regulates gut microbes. [Abstract]

2024 May 24:547:28-36. PMID: 38552734
Discov Med

Network pharmacology-based analysis of mechanisms of the anti-hepatocellular carcinoma effect by dihydroartemisinin. [Abstract]

2019 Sep;28(153):139-147. PMID: 31926585
Kaohsiung J Med Sci

Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis. [Abstract]

2023 Jul;39(7):699-709. PMID: 37057810

Dihydroartemisinin purchased from MedChemExpress. Usage Cited in: Kaohsiung J Med Sci. 2023 Jul;39(7):699-709. [Abstract]

Dihydroartemisinin (DHA; 12.5, 25, 50 μM; 24 h) significantly reduces the viability of A549-GR cells in a dose-dependent manner.

Dihydroartemisinin purchased from MedChemExpress. Usage Cited in: Kaohsiung J Med Sci. 2023 Jul;39(7):699-709. [Abstract]

Dihydroartemisinin (DHA; 12.5, 25, 50 μM; 24 h) increases the expression of cleaved-Caspase 3, but decreases the expression of PARP and Bcl-2 in A549-GR cells.
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Photodiagnosis Photodyn Ther

Enhancement of the cytotoxic effect of dihydroartemisinin in high-risk human papillomavirus-infected cells by aminolevulinic acid via the Bax/Bcl-2-caspase pathway. [Abstract]

2022 Dec:40:103053. PMID: 35932961
Clin Rheumatol

Dihydroartemisinin alleviates skin fibrosis and endothelial dysfunction in bleomycin-induced skin fibrosis models. [Abstract]

2021 Oct;40(10):4269-4277. PMID: 34013490
Biochem Biophys Res Commun

Ticlopidine protects hepatic ischemia-reperfusion injury via suppressing ferroptosis. [Abstract]

2024 Nov 12:733:150436. PMID: 39053102
Biochem Biophys Res Commun

Dihydroartemisinin potentiates antitumor activity of 5-fluorouracil against a resistant colorectal cancer cell line. [Abstract]

2018 Jun 27;501(3):636-642. PMID: 29738772

Dihydroartemisinin purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2018 Jun 27;501(3):636-642. [Abstract]

Immunoblot analysis of the expression levels of BCL-2 and BAX after treatment of HCT116 TP53^-/- cells with 20 μM 5-FU and 1.25 μM DHA alone or in combination for 48 h. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a loading control.
Leuk Res

Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines. [Abstract]

2021 Nov:110:106702. PMID: 34571432
Oncol Lett

Dihydroartemisinin suppresses proliferation, migration, the Wnt/β-catenin pathway and EMT via TNKS in gastric cancer. [Abstract]

2021 Oct;22(4):688. PMID: 34457043
J Plast Surg Hand Surg

Topical Dihydroartemisinin Improves Wound Healing in Diabetic Mice. [Abstract]

2023 Jun 14:58:26-32. PMID: 37314293
Loughborough University

2025.
Oxid Med Cell Longev

Repurposing Dihydroartemisinin to Combat Oral Squamous Cell Carcinoma, Associated with Mitochondrial Dysfunction and Oxidative Stress. [Abstract]

2023 Feb 16:2023:9595201. PMID: 37273554

Dihydroartemisinin purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2023 Feb 16:2023:9595201. [Abstract]

Dihydroartemisinin (DHA; 50, 100 µM) remarkably inhibits single-cell colony formation of HSC3 cells and SAS cells in a dosage-dependent manner (Fig e and f).
Oxid Med Cell Longev

TUG1/MAZ/FTH1 Axis Attenuates the Antiglioma Effect of Dihydroartemisinin by Inhibiting Ferroptosis. [Abstract]

2022 Sep 17;2022:7843863. PMID: 36164395
Research Square Preprint

2022 Feb.
Biomed Pharmacother

TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib. [Abstract]

2020 Jun:126:109862. PMID: 32120157

Solvant et solubilité

In Vitro:

DMSO : 25 mg/mL (87.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 10 mg/mL (35.17 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5168 mL

17.5840 mL

35.1679 mL

5 mM

0.7034 mL

3.5168 mL

7.0336 mL

10 mM

0.3517 mL

1.7584 mL

3.5168 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (7.31 mM); Suspended solution; Need ultrasonic and warming

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (7.31 mM); Clear solution; Need ultrasonic and warming

This protocol yields a clear solution of 2.08 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: 2.08 mg/mL (7.31 mM); Clear solution; Need warming

This protocol yields a clear solution of 2.08 mg/mL. If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (3.52 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 5

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (3.52 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 6

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 1 mg/mL (3.52 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (291 KB)
SDS (610 KB)
- English - EN (610 KB)
- Français - FR (610 KB)
- Deutsch - DE (610 KB)
- Norwegian - NO (610 KB)
- Español - ES (610 KB)
- Swedish - SV (610 KB)
- Italian - IT (610 KB)
- Korean - KR (610 KB)
- Portuguese - PT (610 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Hu W, et al. Dihydroartemisinin induces autophagy by suppressing NF-κB activation. Cancer Lett. 2014;343(2):239-248. [Content Brief]

[2]. Li YJ, et al. Dihydroartemisinin accentuates the anti-tumor effects of photodynamic therapy via inactivation of NF-κB in Eca109 and Ec9706 esophageal cancer cells. Cell Physiol Biochem. 2014;33(5):1527-1536. [Content Brief]

[3]. Li HJ, et al. Dihydroartemisinin-praziquantel combinations and multiple doses of dihydroartemisinin in the treatment of Schistosoma japonicum in experimentally infected mice. Ann Trop Med Parasitol. 2011 Jun;105(4):329-33. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	3.5168 mL	17.5840 mL	35.1679 mL	87.9198 mL
	5 mM	0.7034 mL	3.5168 mL	7.0336 mL	17.5840 mL
	10 mM	0.3517 mL	1.7584 mL	3.5168 mL	8.7920 mL
	15 mM	0.2345 mL	1.1723 mL	2.3445 mL	5.8613 mL
	20 mM	0.1758 mL	0.8792 mL	1.7584 mL	4.3960 mL
	25 mM	0.1407 mL	0.7034 mL	1.4067 mL	3.5168 mL
	30 mM	0.1172 mL	0.5861 mL	1.1723 mL	2.9307 mL
DMSO	40 mM	0.0879 mL	0.4396 mL	0.8792 mL	2.1980 mL
	50 mM	0.0703 mL	0.3517 mL	0.7034 mL	1.7584 mL
	60 mM	0.0586 mL	0.2931 mL	0.5861 mL	1.4653 mL
	80 mM	0.0440 mL	0.2198 mL	0.4396 mL	1.0990 mL

Dihydroartemisinin

45 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Dihydroartemisinin

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

NMPA-Approved Drug Library

Terpenoids Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Drug Metabolite Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Drug Fragment Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Dihydroartemisinin

Voir tous les produits spécifiques à Isoform Parasite

Voir tous les produits spécifiques à Isoform NF-κB

Activité biologique

Chemical Information

Publications (45)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs